Guardant Health, Inc. (FRA:5GH)
Germany · Delayed Price · Currency is EUR | Market Cap | 14.82B +227.9% |
| Revenue (ttm) | 936.87M +39.6% |
| Net Income | -375.71M |
| EPS | -2.95 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 111.48 |
| Previous Close | 109.50 |
| Day's Range | 111.48 - 111.48 |
| 52-Week Range | 35.65 - 113.92 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About Guardant Health
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transc... [Read more]
Financial Performance
In 2025, Guardant Health's revenue was $982.02 million, an increase of 32.88% compared to the previous year's $739.02 million. Losses were -$416.28 million, -4.61% less than in 2024.
Financial numbers in USD Financial StatementsNews
Guardant Health Transcript: 46th Annual William Blair Growth Stock Conference
Strong innovation and commercial execution are driving rapid revenue growth, with multiple products addressing large oncology and screening markets. Shield’s adoption is accelerating, supported by guideline inclusion and strategic partnerships, while financial discipline positions the business for sustained profitability and cash flow breakeven by 2027.
Guardant Health upgraded to Outperform from In Line at Evercore ISI
Evercore ISI upgraded Guardant Health (GH) to Outperform from In Line with a price target of $160, up from $95. G360 ADLT pricing of $8,455 should lead to average selling…
Guardant Health assumed with an Outperform at Wolfe Research
Wolfe Research analyst Paige Chamberlain assumed coverage of Guardant Health (GH) with an Outperform rating and price target of $150, up from $120. Wolfe names Guardant its top idea in…
Guardant Health to present 38 abstracts at ASCO 2026 meeting
Guardant Health (GH) announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer (PFE), showcasing advances in methylati...
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstrac...
Guardant Health management to meet with Craig-Hallum
Meeting to be held in Chicago on June 1 hosted by Craig-Hallum.
Guardant Health price target raised to $160 from $155 at BTIG
BTIG raised the firm’s price target on Guardant Health (GH) to $160 from $155 and keeps a Buy rating on the shares. The American Cancer Society updated its guidelines for…
ACS recommends Guardant Health’s Shield blood test in screening guidelines
Guardant Health (GH) announced that its FDA-approved Shield(TM) blood test is now included in updated American Cancer Society Colorectal Cancer Screening Guidelines published today. The major screenin...
American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield™ blood test is now included in updated American Can...
Blood test added to US colorectal cancer screening options
People who skip colorectal cancer screening because colonoscopy or stool testing seems too burdensome now have a blood test option from Guardant Health among recommendations by the American Cancer S...
Guardant Health management to meet with Craig-Hallum
Meeting to be held in Chicago on June 1 hosted by Craig-Hallum.
Guardant Health price target raised to $155 from $145 at BTIG
BTIG raised the firm’s price target on Guardant Health (GH) to $155 from $145 and keeps a Buy rating on the shares. Medicare fee-for-service represents about 20%-25% of Guardant’s volumes,…
Guardant Health announces U.S. FDA approved Guardant360 Liquid CDx
Guardant Health (GH) announced that the U.S. Food and Drug Administration, FDA, has approved Guardant360 Liquid CDx, advancing blood-based comprehensive genomic testing by integrating genomic and epig...
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360®...
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 21, 2026, the Compensation Committee of Guardant's Board of ...
Guardant Health Transcript: Bank of America Global Healthcare Conference 2026
Strong Q1 results led to raised full-year guidance, driven by oncology and Shield volumes, with further upside expected from ACS guideline changes and operational investments. AI and data-driven platforms are accelerating growth and market share, while robust compliance and strategic investments support long-term expansion.
Guardant Health price target raised to $135 from $130 at Piper Sandler
Piper Sandler analyst David Westenberg raised the firm’s price target on Guardant Health (GH) to $135 from $130 and keeps an Overweight rating on the shares. The firm believes Guardant…
Guardant Health price target raised to $95 from $90 at Evercore ISI
Evercore ISI analyst Vijay Kumar raised the firm’s price target on Guardant Health (GH) to $95 from $90 and keeps an In Line rating on the shares. Published first on…
Guardant Health price target raised to $129 from $120 at Baird
Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Guardant Health (GH) to $129 from $120 and keeps an Outperform rating on the shares. The firm updated its…
Guardant Health price target raised to $135 from $130 at JPMorgan
JPMorgan raised the firm’s price target on Guardant Health (GH) to $135 from $130 and keeps an Overweight rating on the shares.
Guardant Health price target raised to $120 from $115 at Barclays
Barclays raised the firm’s price target on Guardant Health (GH) to $120 from $115 and keeps an Overweight rating on the shares.
Guardant Health reports Q1 adjusted EPS (45c), consensus (47c)
Reports Q1 revenue $301.7M, consensus $279.06M. “Our first-quarter revenue increased 48% year over year, reflecting strong momentum across the Guardant portfolio,” said Helmy Eltoukhy, co-founder and ...
Guardant Health raises FY26 revenue view to $1.3B-$1.32B from $1.25B-$1.28B
Consensus $1.27B. Guardant Health (GH) continues to expect full year 2026 non-GAAP gross margin to be in the range of 64% to 65%. Guardant Health now expects total non-GAAP operating…
Guardant Health Earnings Call Transcript: Q1 2026
Q1 2026 saw 48% revenue growth to $302M, driven by strong oncology, biopharma, and screening performance. Raised full-year guidance to $1.30–$1.32B, with Shield and Guardant360 products leading growth and continued investment in commercial expansion.
Guardant Health Earnings release: Q1 2026
Guardant Health released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.